The two final sets of ASCO-related data (on a polyphenol-rich food supplement and curcuminoids)


Here is the last of our data-based reports from the annual meeting of the American Society for Clinical Oncology (ASCO), which ended last Tuesday. It deals with two presentations that are at least intellectually interesting but do not as yet “translate” into any type of clinical certainty.

In the first presentation, entitled “A double-blind, placebo RCT evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer: The U.K. National Cancer Research Network (NCRN) Pomi-T study“, Thomas et al. discuss the effects of a polyphenol-rich blend of pomegranate seed, green tea, broccoli, and turmeric (Pomi-T) or an identical placebo for 6 months in the management of men initially diagnosed with localized prostate cancer. Information about this trial was published earlier (in the UK) in The Daily Telegraph under the heading “‘Superfoods’ shown to fight prostate cancer” — a typically newspaper-like headline!

This study involved > 200 men in a randomized, double-blind, controlled, Phase II clinical trial. All patients received either an oral capsule containing the food supplement twice a day or they received an identical placebo. Here are the early trial results:

  • 203 men diagnosed with localized prostate cancer were enrolled into the trial.
    • The average age of the patients was 74 years.
    • 59 percent were being managed with active surveillance.
    • 41 percent were being managed with watchful waiting (progressive PSA relapse following previous radical interventions).
  • The patients were randomized into two groups (to receive either the food supplement or the placebo).
    • The groups were statistically balanced in terms of Gleason grade, body mass index (BMI), treatment category, and fasting cholesterol.
    • Men in the food supplement group were younger (average age 71.8 years) than men in the placebo group (average age 76.4 years).
    • Four men withdrew from the study after randomization.
  • The average (median) change in PSA levels of men in the two groups at 6 months was:
    • +14.7 percent for the men receiving the food supplement
    • +78.5 percent for the men receiving the placebo
    • This difference is statistically significant.
  • At 6 months, stable or lower PSA levels were observed in
    • 46 percent of men receiving the food supplement
    • 14 percent of the men receiving the placebo.
    • This difference is statistically significant.
  • There were no significant differences in change of PSA level within the predetermined subgroups (age, Gleason grade, treatment category, BMI).
  • There were no significant differences in cholesterol, blood pressure, blood sugar or c-reactive protein.
  • Data on reports of side effects were as follows:
    • 24 percent of men receiving the food supplement reported such events.
    • 34 percent of men receiving the placebo reported such events.
    • This difference was not statistically significant.
    • Mild gastrointestinal effects were reported by 17 percent of men receiving the food supplement in the FSG but 8 percent of these men reported an improvement in stool quality.

The authors conclude that, “This study found a statistically significant, short-term, favorable effect on the percentage rise in PSA in these men managed with observation following intake of this specific food supplement.”

This particular food supplement is commercially available at this time … at least in the UK and the USA, but the authors of the paper all state that they had “No relationships to disclose” and so we assume that the manufacturer was not in any way involved with this trial. The authors also state that “future trials should look at the longer-term clinical benefits particularly in terms of preventing medical intervention.”

This study does certainly add further support to the existing evidence that older men with (potentially) lower risk forms of prostate cancer or men who are on watchful waiting after first-line therapy may be able to allay PSA-related stress while on active surveillance or other forms of expectant management through dietary interventions. We do not yet know whether such dietary interventions have any impact on overall survival in such men.

Certainly some men may feel that they may want to add this particular food supplement to their diets based on the above information. The “New” Prostate Cancer InfoLink would only note that, if you want to do that, you might want to show the results of this study to your doctor and discuss them with him/her before you proceed. (An additional article about this study appeared on the Medscape web site on Monday July 10.)

In the second of these two presentations, Mahammedi et al. have suggested — based on data from a small Phase II clinical trial — that adding products known as curcumoinoids (derived from the herb known as turmeric) to docetaxel-based chemotherapy can significantly lower PSA levels and extend progression-free survival among men with castrate-resistant prostate cancer (CRPC).

A complete discussion of this paper is available on the CancerNetwork.com web site where Dr. Mahammedi is quoted as stating,

I think that the combination of curcuminoids and docetaxel has the potential in the future to enhance the efficacy of chemotherapy with no additional toxicity. If the studies are positive we can expect to take purified curcuminoid for a long time to neutralize the spread of cancer.

However, note the caution in the statement from Dr. Derek Rhaghavan, who says that that the information provided in the abstract is insufficient “to assess the utility of this novel compound.” He goes on to observe that, “The patient population is poorly characterized, the definition of progression is unclear, and there appears to be an absence of strong preclinical modeling data.”

The “New” Prostate Cancer InfoLink would point out simply that turmeric was a component of the food supplement used in the Pomi-T trial discussed above. One has to wonder whether a simple dietary intervention in combination with docetaxel-based chemotherapy might have similar effects to docetaxel + curcuminoids.

2 Responses

  1. WOW!!!

    Thanks for pointing out these studies, particularly the one involving the four combined nutrients.

    I like the design and execution of the Pomi-T study, and I especially like those strong results! Just one likely small exception here: PSA doubling time (PSADT) was not part of the stratification scheme, yet the change in PSA level was the key endpoint. Hopefully the size of the study and randomization sufficed to equalize PSADT in the two arms of the study, and there is a sentence in the abstract that suggests that was the case: “There were no significant differences in PSA% change within the predetermined subgroups (age, gleason grade, treatment category, BMI).” Does anyone have insight into why PSADT was not part of the scheme, or why it was not necessary?

    I find it most encouraging that the favorable results in the four nutrient study are consistent with two earlier clinical trials involving pomegranate juice and pomegranate extract, the first by UCLA and the second by Johns Hopkins. I hope some researchers will follow-up this study with one pitting Pomi-T versus one of the quality pomegranate extract capsules. That would help tease out the extent to which pomegranate was responsible for the results, which strike me as similar to results for pomegranate juice or capsules alone. I’m sure a lot of us would like to know if there is synergy here. Doses also matter, of course, and the specific sources of the nutrients in the pill may also be important. For instance, two quality pomegranate extract capsules I know of, each backed by research, use a combination of elements from the pomegranate, not just the seed, based on results of “heat map” genetic testing.

    Nutrition and other lifestyle tactics have long been a part of my program, and all four nutrients studied here, in various forms, have been important in my program. I took a pomegranate extract capsule for years prior to recent radiation. I eat a lightly steamed serving of broccoli, with mustard and a radish which improve absorption, almost daily and have done so for years. I typically drink 8 bags worth of green tea (two 12-oz mugs with two bags each, at breakfast and again at lunch), with several drops of lemon juice to minimize oxidation, stirred, and steeped for 10 minutes, a recent research-based increase from 5 minutes. Prior to radiation I was able to tolerate 10 Super Bio Curcumin capsules a day, but have not yet resumed curcumin; I’m thinking I’ll need a lower dose due to the lingering mild gastrointestinal side effects of radiation. I had been taking some level of curcumin for several years.

    I credit lifestyle tactics with putting me in a situation where an attempt at cure with modern imaging and other technology was possible this spring, despite a challenging start to my cancer journey in December 1999. Dr. Charles “Snuffy” Myers, known to many of us, has been advocating consumption of all of these nutrients for years. He is convinced there typically are favorable changes in patients in his own practice who have used these lifestyle tactics.

  2. Jim Waldenfels:

    You mention two quality pomegranate extracts. Could you give us the names of the extracts?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: